Relovair fluticasone furoate/vilanterol: Phase II data

In a double-blind Phase II trial in 60 patients, Relovair fluticasone furoate/vilanterol (400/25 µg) met the co-primary safety endpoint of non-inferiority to placebo in change from baseline in weighted mean heart rate from 0-4 hours post-dose at day 28. On the other co-primary safety endpoint, rates of adverse events were 68% and 50% for Relovair and placebo, respectively. The most common adverse events reported were nasopharyngitis, headache, dizziness and candidiasis. ...